Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H20N2O3 |
Molecular Weight | 312.363 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(CCNCC2=C(O)C=CC=C2)=C(OC)C=C1C#N
InChI
InChIKey=VWEDZTZAXHMZIL-UHFFFAOYSA-N
InChI=1S/C18H20N2O3/c1-22-17-10-15(11-19)18(23-2)9-13(17)7-8-20-12-14-5-3-4-6-16(14)21/h3-6,9-10,20-21H,7-8,12H2,1-2H3
Molecular Formula | C18H20N2O3 |
Molecular Weight | 312.363 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24397362Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25224567
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24397362
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25224567
25CN-NBOH (or NBOH-2C-CN) is a compound indirectly derived from the phenethylamine series of hallucinogens, which was discovered in 2011 by Martin Hansen at the University of Copenhagen. This compound is notable as one of the most selective agonist ligands for the 5-HT2A receptor yet discovered, with a pKi of 8.88 at the human 5-HT2A receptor and with 100x selectivity for 5-HT2A over 5-HT2C, and 46x selectivity for 5-HT2A over 5-HT2B
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2490 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24397362 |
1.3 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25224567
Male NIH Swiss mice were used for activity evaluation. On experimental days, mice were weighed, marked, and returned to the home cage. Doses were then calculated and prepared for intraperitoneal (ip) injection. To generate dose effect functions, individual animals were removed from the home cage, injected with saline or various doses of 25CN-NBOH (0.3, 3 and 10mk/kg) and placed into an observation cage containing fresh bedding. Ten minutes following this injection, an overhead camera was activated and behavior was recorded for 10 min.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24397362
The day after transfection, tsA201 cells were split into poly-D-lysine-coated 96-well tissue culture plates in inositol-free DMEM supplemented with 10% dialyzed fetal bovine serum, penicillin (100 U mL−1), streptomycin (100 mg mL−1), and 4 μCi mL−1 myo-[2-3H]inositol (GE Healthcare, Buckinghamshire, U.K.). Two days after transfection, cells were washed with assay buffer 1 (Hanks’ balanced saline solution (HBSS) containing 20 mM HEPES, 1 mM CaCl2, 1 mM MgCl2, and 1 mg mL−1 BSA, pH 7.4) and preincubated in 100 μL assay buffer 1 for 4 h at 37 °C, where the buffer was replaced after 2 h. The cells were then washed and subsequently incubated in 50 μL of assay buffer 2 (HBSS containing 1 mM CaCl2, 1 mM MgCl2, and 20 mM LiCl) for 30 min at 37 °C. Following this incubation, the cells were stimulated with 50 μL of the NBOH-2C-CN in assay buffer 2 for 30 min at 37 °C. The reactions were stopped by exchanging the buffer with 50 μL ice-cold 10 mM formic acid and incubating the cells at 4 °C for at least 30 min. Yttrium silicate scintillation proximity assay beads (GE Healthcare, Buckinghamshire, U.K.) were used for measuring radioactivity from generated [3H]-IP
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:15:23 GMT 2023
by
admin
on
Sat Dec 16 18:15:23 GMT 2023
|
Record UNII |
32CN2DQE3Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
25CN-NBOH
Created by
admin on Sat Dec 16 18:15:23 GMT 2023 , Edited by admin on Sat Dec 16 18:15:23 GMT 2023
|
PRIMARY | |||
|
145979
Created by
admin on Sat Dec 16 18:15:23 GMT 2023 , Edited by admin on Sat Dec 16 18:15:23 GMT 2023
|
PRIMARY | |||
|
90489020
Created by
admin on Sat Dec 16 18:15:23 GMT 2023 , Edited by admin on Sat Dec 16 18:15:23 GMT 2023
|
PRIMARY | |||
|
DTXSID30101725
Created by
admin on Sat Dec 16 18:15:23 GMT 2023 , Edited by admin on Sat Dec 16 18:15:23 GMT 2023
|
PRIMARY | |||
|
32CN2DQE3Q
Created by
admin on Sat Dec 16 18:15:23 GMT 2023 , Edited by admin on Sat Dec 16 18:15:23 GMT 2023
|
PRIMARY | |||
|
1391489-32-9
Created by
admin on Sat Dec 16 18:15:23 GMT 2023 , Edited by admin on Sat Dec 16 18:15:23 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->PARTIAL AGONIST |
BINDING
Ki
|
||
|
TARGET -> AGONIST |
Assumed agonist
Ki
|
||
|
TARGET -> AGONIST |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> DERIVATIVE |
|